PMC:7105881 / 58561-59627 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1754","span":{"begin":115,"end":124},"obj":"Species"},{"id":"1755","span":{"begin":148,"end":154},"obj":"Species"},{"id":"1756","span":{"begin":291,"end":306},"obj":"Species"},{"id":"1757","span":{"begin":359,"end":367},"obj":"Species"},{"id":"1758","span":{"begin":373,"end":381},"obj":"Species"},{"id":"1759","span":{"begin":468,"end":473},"obj":"Species"},{"id":"1760","span":{"begin":474,"end":478},"obj":"Species"},{"id":"1761","span":{"begin":519,"end":528},"obj":"Species"},{"id":"1762","span":{"begin":598,"end":613},"obj":"Species"},{"id":"1763","span":{"begin":664,"end":673},"obj":"Species"},{"id":"1764","span":{"begin":273,"end":282},"obj":"Disease"},{"id":"1765","span":{"begin":1046,"end":1065},"obj":"Disease"}],"attributes":[{"id":"A1754","pred":"tao:has_database_id","subj":"1754","obj":"Tax:2697049"},{"id":"A1755","pred":"tao:has_database_id","subj":"1755","obj":"Tax:9606"},{"id":"A1756","pred":"tao:has_database_id","subj":"1756","obj":"Tax:2697049"},{"id":"A1757","pred":"tao:has_database_id","subj":"1757","obj":"Tax:694009"},{"id":"A1758","pred":"tao:has_database_id","subj":"1758","obj":"Tax:1335626"},{"id":"A1759","pred":"tao:has_database_id","subj":"1759","obj":"Tax:9606"},{"id":"A1760","pred":"tao:has_database_id","subj":"1760","obj":"Tax:11118"},{"id":"A1761","pred":"tao:has_database_id","subj":"1761","obj":"Tax:2697049"},{"id":"A1762","pred":"tao:has_database_id","subj":"1762","obj":"Tax:2697049"},{"id":"A1763","pred":"tao:has_database_id","subj":"1763","obj":"Tax:2697049"},{"id":"A1764","pred":"tao:has_database_id","subj":"1764","obj":"MESH:D007239"},{"id":"A1765","pred":"tao:has_database_id","subj":"1765","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Rapid Development of Subunit Vaccines Against the New Pathogenic Human Coronavirus\nCurrently, the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against this new coronavirus (Jiang et al., 2020). Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T331","span":{"begin":316,"end":323},"obj":"Body_part"},{"id":"T332","span":{"begin":709,"end":716},"obj":"Body_part"},{"id":"T333","span":{"begin":723,"end":730},"obj":"Body_part"}],"attributes":[{"id":"A331","pred":"fma_id","subj":"T331","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A332","pred":"fma_id","subj":"T332","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A333","pred":"fma_id","subj":"T333","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Rapid Development of Subunit Vaccines Against the New Pathogenic Human Coronavirus\nCurrently, the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against this new coronavirus (Jiang et al., 2020). Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T280","span":{"begin":273,"end":282},"obj":"Disease"},{"id":"T281","span":{"begin":359,"end":367},"obj":"Disease"},{"id":"T282","span":{"begin":888,"end":892},"obj":"Disease"},{"id":"T283","span":{"begin":1046,"end":1065},"obj":"Disease"},{"id":"T284","span":{"begin":1056,"end":1065},"obj":"Disease"}],"attributes":[{"id":"A280","pred":"mondo_id","subj":"T280","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A281","pred":"mondo_id","subj":"T281","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A282","pred":"mondo_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A283","pred":"mondo_id","subj":"T283","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A284","pred":"mondo_id","subj":"T284","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Rapid Development of Subunit Vaccines Against the New Pathogenic Human Coronavirus\nCurrently, the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against this new coronavirus (Jiang et al., 2020). Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T673","span":{"begin":65,"end":70},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T674","span":{"begin":468,"end":473},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T675","span":{"begin":685,"end":687},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T676","span":{"begin":692,"end":694},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T677","span":{"begin":692,"end":694},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"}],"text":"Rapid Development of Subunit Vaccines Against the New Pathogenic Human Coronavirus\nCurrently, the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against this new coronavirus (Jiang et al., 2020). Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T25253","span":{"begin":316,"end":323},"obj":"Chemical"},{"id":"T63058","span":{"begin":692,"end":694},"obj":"Chemical"},{"id":"T52663","span":{"begin":709,"end":716},"obj":"Chemical"},{"id":"T29983","span":{"begin":723,"end":730},"obj":"Chemical"}],"attributes":[{"id":"A79894","pred":"chebi_id","subj":"T25253","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A919","pred":"chebi_id","subj":"T63058","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"},{"id":"A63200","pred":"chebi_id","subj":"T52663","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A59046","pred":"chebi_id","subj":"T29983","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Rapid Development of Subunit Vaccines Against the New Pathogenic Human Coronavirus\nCurrently, the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against this new coronavirus (Jiang et al., 2020). Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection."}

{"project":"2_test","denotations":[{"id":"32265848-32005086-36511237","span":{"begin":629,"end":633},"obj":"32005086"}],"text":"Rapid Development of Subunit Vaccines Against the New Pathogenic Human Coronavirus\nCurrently, the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against this new coronavirus (Jiang et al., 2020). Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection."}

{"project":"LitCovid-sentences","denotations":[{"id":"T312","span":{"begin":0,"end":82},"obj":"Sentence"},{"id":"T313","span":{"begin":83,"end":197},"obj":"Sentence"},{"id":"T314","span":{"begin":198,"end":307},"obj":"Sentence"},{"id":"T315","span":{"begin":308,"end":635},"obj":"Sentence"},{"id":"T316","span":{"begin":636,"end":794},"obj":"Sentence"},{"id":"T317","span":{"begin":795,"end":1066},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Rapid Development of Subunit Vaccines Against the New Pathogenic Human Coronavirus\nCurrently, the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against this new coronavirus (Jiang et al., 2020). Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T974","span":{"begin":65,"end":70},"obj":"SP_6;NCBITaxon:9606"},{"id":"T975","span":{"begin":71,"end":82},"obj":"NCBITaxon:11118"},{"id":"T976","span":{"begin":115,"end":124},"obj":"SP_7"},{"id":"T977","span":{"begin":148,"end":154},"obj":"NCBITaxon:9606"},{"id":"T978","span":{"begin":295,"end":306},"obj":"NCBITaxon:11118"},{"id":"T979","span":{"begin":314,"end":323},"obj":"PG_1"},{"id":"T980","span":{"begin":359,"end":367},"obj":"SP_10"},{"id":"T981","span":{"begin":373,"end":381},"obj":"SP_9"},{"id":"T982","span":{"begin":468,"end":473},"obj":"SP_6;NCBITaxon:9606"},{"id":"T983","span":{"begin":519,"end":528},"obj":"SP_7"},{"id":"T984","span":{"begin":602,"end":613},"obj":"NCBITaxon:11118"},{"id":"T985","span":{"begin":664,"end":673},"obj":"SP_7"},{"id":"T986","span":{"begin":707,"end":716},"obj":"PG_1;PR:000005292"},{"id":"T987","span":{"begin":721,"end":730},"obj":"PG_4"},{"id":"T988","span":{"begin":888,"end":892},"obj":"SP_10"},{"id":"T989","span":{"begin":897,"end":901},"obj":"SP_9"},{"id":"T990","span":{"begin":1046,"end":1055},"obj":"SP_7"},{"id":"T67154","span":{"begin":65,"end":70},"obj":"SP_6;NCBITaxon:9606"},{"id":"T34707","span":{"begin":71,"end":82},"obj":"NCBITaxon:11118"},{"id":"T12447","span":{"begin":115,"end":124},"obj":"SP_7"},{"id":"T36976","span":{"begin":148,"end":154},"obj":"NCBITaxon:9606"},{"id":"T19359","span":{"begin":295,"end":306},"obj":"NCBITaxon:11118"},{"id":"T78099","span":{"begin":314,"end":323},"obj":"PG_1"},{"id":"T46216","span":{"begin":359,"end":367},"obj":"SP_10"},{"id":"T64127","span":{"begin":373,"end":381},"obj":"SP_9"},{"id":"T79853","span":{"begin":468,"end":473},"obj":"SP_6;NCBITaxon:9606"},{"id":"T74733","span":{"begin":519,"end":528},"obj":"SP_7"},{"id":"T2395","span":{"begin":602,"end":613},"obj":"NCBITaxon:11118"},{"id":"T36328","span":{"begin":664,"end":673},"obj":"SP_7"},{"id":"T15893","span":{"begin":707,"end":716},"obj":"PG_1;PR:000005292"},{"id":"T95872","span":{"begin":721,"end":730},"obj":"PG_4"},{"id":"T98863","span":{"begin":888,"end":892},"obj":"SP_10"},{"id":"T53939","span":{"begin":897,"end":901},"obj":"SP_9"},{"id":"T5172","span":{"begin":1046,"end":1055},"obj":"SP_7"}],"text":"Rapid Development of Subunit Vaccines Against the New Pathogenic Human Coronavirus\nCurrently, the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against this new coronavirus (Jiang et al., 2020). Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection."}